Behbahani Ali
CIK 0001613867 Name as filed on the most recent filing
Filed as Behbahani Ali (27)
37 transaction lines · from 27 filings · filed 2018-09-10 to 2026-02-11 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER SpyGlass Pharma, Inc. 1 filings
- ISSUER NeueHealth, Inc. 2 filings
- ISSUER Adaptimmune Therapeutics PLC 3 filings
- ISSUER Marker Therapeutics, Inc. 2 filings
- ISSUER MBX Biosciences, Inc. 1 filings
- ISSUER Savara Inc 1 filings
- ISSUER Black Diamond Therapeutics, Inc. 2 filings
- ISSUER Genocea Biosciences, Inc. 4 filings
- ISSUER Trevi Therapeutics, Inc. 4 filings
- ISSUER Metacrine, Inc. 2 filings
- ISSUER Monte Rosa Therapeutics, Inc. 1 filings
- ISSUER Regulus Therapeutics Inc. 2 filings
- ISSUER Akouos, Inc. 1 filings
- ISSUER Mirum Pharmaceuticals, Inc. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
36 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-02-09 |
SpyGlass Pharma, Inc. SGP |
P, Open-market purchase | 937,500 acquired | 16.00 | 15,000,000.00 | Form 4, filing 0001193125-26-046676 | |
| 2025-10-02 |
NeueHealth, Inc. NEUE |
S, Open-market sale | 2,455 disposed | 6.75 | 16,571.25 | Form 4, filing 0001193125-25-232141 | |
| 2025-10-02 |
NeueHealth, Inc. NEUE |
S, Open-market sale | 900 disposed | 6.75 | 6,075.00 | Form 4, filing 0001193125-25-232141 | |
| 2025-10-02 |
NeueHealth, Inc. NEUE |
S, Open-market sale | 280 disposed | 6.75 | 1,890.00 | Form 4, filing 0001193125-25-232141 | |
| 2025-10-02 |
NeueHealth, Inc. NEUE |
S, Open-market sale | 280 disposed | 6.75 | 1,890.00 | Form 4, filing 0001193125-25-232141 | |
| 2025-08-18 |
Adaptimmune Therapeutics PLC ADAP |
S, Open-market sale | 14,671,794 disposed | 0.01 | 176,061.53 | Form 4, filing 0000950170-25-110254 | |
| 2025-08-15 |
Adaptimmune Therapeutics PLC ADAP |
S, Open-market sale | 4,828,206 disposed | 0.01 | 53,110.27 | Form 4, filing 0000950170-25-110254 | |
| 2024-12-23 |
Marker Therapeutics, Inc. MRKR |
P, Open-market purchase | 554,250 acquired | 3.20 | 1,773,600.00 | Form 4, filing 0000950170-24-139630 | |
| 2024-09-16 |
MBX Biosciences, Inc. MBX |
P, Open-market purchase | 500,000 acquired | 16.00 | 8,000,000.00 | Form 4, filing 0000950170-24-107554 | |
| 2023-07-17 |
Savara Inc SVRA |
P, Open-market purchase | 333,333 acquired | 3.00 | 999,999.00 | Form 4, filing 0001209191-23-042797 | |
| 2023-07-05 |
Black Diamond Therapeutics, Inc. BDTX |
P, Open-market purchase | 1,000,000 acquired | 5.00 | 5,000,000.00 | Form 4, filing 0001209191-23-041567 | |
| 2022-05-25 |
Genocea Biosciences, Inc. GNCA |
S, Open-market sale | 4,445,093 disposed | 0.08 | 362,719.59 | Form 4, filing 0001209191-22-032320 | |
| 2022-05-24 |
Genocea Biosciences, Inc. GNCA |
S, Open-market sale | 5,931,843 disposed | 0.07 | 387,942.53 | Form 4, filing 0001209191-22-032320 | |
| 2022-04-11 |
Trevi Therapeutics, Inc. TRVI |
P, Open-market purchase | 2,631,578 acquired | 1.90 | 4,999,998.20 | Form 4, filing 0001209191-22-024314 | |
| 2022-04-11 |
Trevi Therapeutics, Inc. TRVI |
P, Open-market purchase | 948,948 acquired | 1.90 | 1,803,001.20 | Form 4, filing 0001209191-22-024314 | |
| 2021-12-22 |
Metacrine, Inc. MTCR |
S, Open-market sale | 288,768 disposed | 1.00 | 289,287.78 | Form 4, filing 0001209191-21-071267 | |
| 2021-12-22 |
Metacrine, Inc. MTCR |
S, Open-market sale | 170,932 disposed | 0.91 | 155,565.21 | Form 4, filing 0001209191-21-071267 | |
| 2021-12-10 |
Metacrine, Inc. MTCR |
S, Open-market sale | 37,570 disposed | 1.32 | 49,629.97 | Form 4, filing 0001209191-21-071267 | |
| 2021-10-18 |
Trevi Therapeutics, Inc. TRVI |
P, Open-market purchase | 1,851,852 acquired | Not reported | Not priced | Form 4, filing 0001209191-21-061092 | |
| 2021-06-28 |
Bright Health Group Inc. BHG |
P, Open-market purchase | 1,694,444 acquired | 18.00 | 30,499,992.00 | Form 4, filing 0001209191-21-044189 | |
| 2021-06-28 |
Bright Health Group Inc. BHG |
P, Open-market purchase | 250,000 acquired | 18.00 | 4,500,000.00 | Form 4, filing 0001209191-21-044189 | |
| 2021-06-28 |
Monte Rosa Therapeutics, Inc. GLUE |
P, Open-market purchase | 1,050,000 acquired | 19.00 | 19,950,000.00 | Form 4, filing 0001209191-21-044037 | |
| 2021-03-16 |
Marker Therapeutics, Inc. MRKR |
P, Open-market purchase | 5,714,285 acquired | 1.75 | 9,999,998.75 | Form 4, filing 0001209191-21-021811 | |
| 2020-12-04 |
Regulus Therapeutics Inc. RGLS |
P, Open-market purchase | 4,398,602 acquired | 0.62 | 2,735,930.44 | Form 4, filing 0001209191-20-061965 | |
| 2020-09-18 |
Metacrine, Inc. MTCR |
P, Open-market purchase | 769,230 acquired | 13.00 | 9,999,990.00 | Form 4, filing 0001209191-20-051527 | |
| 2020-07-24 |
Genocea Biosciences, Inc. GNCA |
P, Open-market purchase | 3,151,260 acquired | 2.25 | 7,090,335.00 | Form 4, filing 0001209191-20-043865 | |
| 2020-06-30 |
Akouos, Inc. AKUS |
P, Open-market purchase | 588,235 acquired | 17.00 | 9,999,995.00 | Form 4, filing 0001209191-20-039857 | |
| 2020-04-03 |
Trevi Therapeutics, Inc. TRVI |
S, Open-market sale | 564 disposed | 2.66 | 1,500.24 | Form 4, filing 0001209191-20-024281 | |
| 2020-02-03 |
Black Diamond Therapeutics, Inc. BDTX |
P, Open-market purchase | 800,000 acquired | 19.00 | 15,200,000.00 | Form 4, filing 0001209191-20-007022 | |
| 2020-01-24 |
Adaptimmune Therapeutics PLC ADAP |
P, Open-market purchase | 7,500,000 acquired | 0.67 | 5,000,250.00 | Form 4, filing 0001209191-20-005167 | |
| 2019-07-22 |
Mirum Pharmaceuticals, Inc. MIRM |
P, Open-market purchase | 450,000 acquired | 15.00 | 6,750,000.00 | Form 4, filing 0001209191-19-043055 | |
| 2019-06-24 |
Genocea Biosciences, Inc. GNCA |
P, Open-market purchase | 2,857,142 acquired | 3.50 | 9,999,997.00 | Form 4, filing 0001209191-19-038955 | |
| 2019-05-09 |
Trevi Therapeutics, Inc. TRVI |
P, Open-market purchase | 1,500,000 acquired | 10.00 | 15,000,000.00 | Form 4, filing 0001209191-19-029394 | |
| 2019-05-09 |
Trevi Therapeutics, Inc. TRVI |
P, Open-market purchase | 1,000,000 acquired | 10.00 | 10,000,000.00 | Form 4, filing 0001209191-19-029394 | |
| 2019-05-07 |
Regulus Therapeutics Inc. RGLS |
P, Open-market purchase | 1,136,704 acquired | 1.08 | 1,227,640.32 | Form 4, filing 0001209191-19-028593 | |
| 2019-02-14 |
Genocea Biosciences, Inc. GNCA |
P, Open-market purchase | 9,948,269 acquired | 0.47 | 4,688,619.18 | Form 4, filing 0001209191-19-011154 | |
| 2018-09-07 |
Adaptimmune Therapeutics PLC ADAP |
P, Open-market purchase | 12,000,000 acquired | 1.67 | 20,000,400.00 | Form 4, filing 0001209191-18-050283 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 24
- Open-market sale 12
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Behbahani Ali, insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001613867
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6